Ricardo Perdigão Henriques, PhD

Managing Partner

Ricardo Perdigão Henriques is the Managing Partner of Biovance Capital. Ricardo is a Harvard and MIT-educated scientist turned investor with experience in scientific research, drug development, venture capital licensing, business development and market analysis.
Ricardo has over 17 years of experience in the biomedical sector in USA and Portugal. Prior to co-founding Biovance Capital, he was the CEO of Bionova Capital, a venture capital firm that invested in health startups across Europe. At Bionova, he invested in the oncology startup CellmAbs that was sold to BioNTech potentially for more than € 1 billion, the largest-ever biotech deal in Portugal.
Ricardo was previously an international business analyst at BIAL, an international R&D-based pharmaceutical company headquartered in Portugal that has developed two proprietary CNS drugs currently in the global market.
Ricardo was an investment manager at Portugal Ventures where he managed a portfolio of six biotech companies and scouted for new deals. Portugal Ventures is the largest venture capital firm in Portugal with 100+ portfolio companies.
Ricardo holds a B.Sc. in Biochemistry and a Ph.D. in Molecular Biology, both approved with the Highest Honors.